Kanti Chittuluru

Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure

Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, Kevin Winthrop et autres

Abrocitinib, an oral, once-daily, Janus kinase 1-selective inhibitor, is efficacious in moderate-to-severe atopic dermatitis with a manageable long-term safety profile. We aimed to provide updated integrated long-term safety results for abrocitinib from available data accrued up to a maximum of almost 4 …

us, fr, dk, gb (code pays fourni par la source)

Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure

Amy S. Paller, Lawrence F. Eichenfield, Jonathan I. Silverberg, Michael J. Cork et autres

Introduction: Abrocitinib, an oral, once-daily, Janus kinase 1–selective inhibitor, was efficacious and well tolerated in adolescent patients with moderate-to-severe atopic dermatitis (AD) exposed for approximately 1 year of treatment. Here, we describe the updated long-term integrated safety profile of abrocitinib in adolescent …

Safety of Intravenous Pantoprazole Sodium in Pediatric Patients Aged 1 Month to < 1 Year: A Real-World Retrospective Cohort Study

Sampada Gandhi, Benjamin Taylor, Lexie Rubens, Nileesa Gautam et autres

us (code pays fourni par la source)

383 Integrated safety analysis of abrocitinib in 635 adolescent patients with moderate-to-severe atopic dermatitis with over 1000 patient-years of exposure

Amy S. Paller, Lawrence F. Eichenfield, Jonathan I. Silverberg, Michael J. Cork et autres

Abstract Abrocitinib is an oral, once-daily, Janus kinase 1–selective inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). Recently, the US Food and Drug Administration expanded the indication of abrocitinib in adolescent patients with moderate-to-severe AD aged 12 to <18 years. …

us, gb, at, ie, de, fr (code pays fourni par la source)

Inhaled nitric oxide after left ventricular assist device implantation: A prospective, randomized, double-blind, multicenter, placebo-controlled trial

Evgenij Potapov, Dan M. Meyer, Madhav Swaminathan, Michael A. E. Ramsay et autres

de, us, gb (code pays fourni par la source)